Literature DB >> 25098804

Tumor lysis syndrome: risk factors, diagnosis, and management.

Rebekah A Burns1, Irina Topoz, Sally L Reynolds.   

Abstract

Tumor lysis syndrome (TLS) is a potentially fatal complication of induction therapy for several types of malignancies. Electrolyte derangements and even downstream complications may also occur prior to the initial presentation to a medical provider, before an oncologic diagnosis has been established. It is therefore imperative that emergency physicians be familiar with the risk factors for TLS in children as well as the criteria for diagnosis and the strategies for prevention and management. Careful evaluation of serum electrolytes, uric acid, and renal function must occur. Patients at risk for TLS and those who already exhibit laboratory or clinical evidence of TLS require close monitoring, aggressive hydration, and appropriate medical treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25098804     DOI: 10.1097/PEC.0000000000000195

Source DB:  PubMed          Journal:  Pediatr Emerg Care        ISSN: 0749-5161            Impact factor:   1.454


  3 in total

1.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.

Authors:  Noel Frey; Michael Bodmer; Andreas Bircher; Susan S Jick; Christoph R Meier; Julia Spoendlin
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

Review 2.  Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature.

Authors:  Vito Emanuele Catania; Michele Vecchio; Michele Malaguarnera; Roberto Madeddu; Giulia Malaguarnera; Saverio Latteri
Journal:  J Med Case Rep       Date:  2017-03-24

3.  Spontaneous tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: a case report.

Authors:  Kai-Bo Chen; Wei-Jia Xie; Yi Huang; Xiao-Li Jin; Guo-Feng Chen; Dan Wu; Jian Chen
Journal:  Transl Cancer Res       Date:  2019-08       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.